The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
The Media Show - Reporting on the Abuse of Power
Philip Marsden discusses some of the ramifications of the UK Government’s approach to Digital Regulation, ahead of the Queen’s Speech this week. For more...